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 ABSTRACT 
 
Photodynamic therapy (PDT) presents an alternative non-invasive therapeutic 
modality for the treatment of cancer and other diseases. PDT relies on cytotoxic singlet 
oxygen that is locally generated through energy transfer between a photosensitizer and 
molecularly dissolved triplet oxygen. To minimize side-effects, i.e. damage of healthy 
tissue, targeted delivery to places of disease, high local photosensitizer concentrations, 
high singlet oxygen quantum yield, and rapid post-treatment clearance of 
photosensitizers are desired. Ultrasmall (sub-10 nm) organic-inorganic hybrid silica 
nanoparticles loaded with photosensitizer molecules, referred to as silica 
nanophotosensitizers (SNPSs), present a way to meet these requirements. Here, we 
investigate two different particle designs of ultrasmall poly(ethylene glycol) coated 
(PEGylated) SNPSs covalently binding the methylene blue derivate MB2. In the first 
approach (design one), MB2 is encapsulated into the silica matrix, while in the second 
approach (design two), MB2 is grafted on the particle surface in between chains of the 
stabilizing PEG corona. We compare both cases with regard to their singlet oxygen 
quantum yields, ΦΔ, with the effective ΦΔeff per particle reaching 111% and 161% for 
design one and two, respectively. Finally, we show that both particle designs allow 
functionalization with a targeting peptide, c(RGDyC), rendering SNPSs a promising 
platform for medical applications.  
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CHAPTER 1 
OVERVIEW  
 
1.1 History and Development of PDT 
Photodynamic therapy (PDT) refers to a combination of light and a 
photosensitive reagent called photosensitizer (PS) to treat diseases [1]. People have 
utilized the therapeutic properties of light for three thousand years to treat different 
diseases including psoriasis, rickets, vitiligo and skin cancer in ancient Egypt, India and 
China [2]. Modern light therapy was introduced by Niels Finsen at the end of the 
nineteenth century, who found that the formation and discharge of smallpox pustules 
could be prevented by being exposed to red light, leading to a Nobel Prize award in 
1903.  In the next hundred years, scientists and researchers developed those light 
induced methods into a combination of light and certain chemicals to cause cell death 
after the introduction of the term ‘photodynamic’ by Von Tappeiner and A. Jesionek 
(Figure 1). 
 
Figure 1. A simplified timeline for the history of photodynamic therapy [1]. 
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Modern PDT was initiated by Frederich Meyer-Berz in 1913 who first tested 
PDT in humans, followed by Richard Lipson in the 1960s who studied a photosensitive 
compound called hematoporphyrin derivative (HPD) that could be selectively localized 
and accumulated in tumor sites [3][4][5]. However, it was not until the 1970s that 
scientists and researchers figured out the therapeutic application of PDT to patients with 
cancer [6]. After that, with a large amount of hard work from scientists all over the 
world, the efficiency of PDT has been gradually improved by developing more selective 
and potent photosensitizers and advanced research equipment. 
PDT consists of two individually non-toxic components: photosensitizer (PS) 
and light. Absorption of light at certain wavelength excites PS molecules from the 
ground state to a triplet excited state. Through collisions in the excited state PS 
molecules transfer energy to ground state oxygen thereby generating reactive oxygen 
species (ROS), such as singlet oxygen and free radicals. Those ROS show cellular 
toxicity and lead to apoptosis or cell death. PSs can be divided into two types by the 
mechanism of singlet oxygen generation [7]. Type I mechanism involves an 
intermediate macromolecule which reacts with a PS first as a carrier of excited electrons 
or hydrogen atoms and then transfers them to molecular triplet oxygen to form cytotoxic 
reactive oxygen species (ROS). On the other hand, type II mechanism involves direct 
energy transfer reaction between a PS and molecular ground state oxygen. PDT induces 
tumor damage through three main pathways: (i) the ROS generated by PDT directly kill 
tumor cells; (ii) PDT damages the tumor-associated vasculature, leading to tumor 
infarction; (iii) PDT activates an immune response against tumor cells.  
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1.2 Thesis Overview  
In this thesis, a well-established nanoparticle platform, i.e. Cornell prime dots 
(C’ dots), was utilized as a new carrier of PSs to localize and accumulate them in specific 
tumor sites (for their synthesis see Figure 2). Well known as ultrasmall sub-10nm 
PEGylated fluorescent core-shell silica nanoparticles that have been translated into the 
clinic, sophisticated particle size control in the sub-10 nm region has successfully been 
reported as well as a versatile surface modification approach to modularly and 
orthogonally functionalize C’ dots with up to four types of different functional ligands 
on the particle surface [8]. Designed as nanoparticles integrating a variety of properties 
including fluorescence detection, specific cell targeting, radioisotope chelating/labeling, 
ratiometric pH sensing, and drug delivery [8], C’ dots are chosen to be a novel PS carrier 
by either incorporating PS molecules inside the silica core or grafting PS molecules on 
the surface among the PEG corona.  
Here, we introduce ultrasmall sub-10 nm organic-inorganic hybrid SNPs 
covalently binding the PS dye MB2, a derivate of methylene blue (MB) (Figure 3B and 
Figure A1). In the following we will refer to these particles as silica 
nanophotosensitizers (SNPSs). MB is a PS molecule that is FDA-approved and has been 
used in photodynamic therapy [9][10], due to its high singlet oxygen quantum yield and 
extinction coefficient in the near infrared (ΦΔ ≈0.5, ε = 105 M-1 cm-1 at 664 nm). Despite 
earlier attempts to synthesize MB containing SNPs, to the best of our knowledge sub-
10 nm functionalized SNPs covalently binding MB have not been reported to date 
[11][12][13].  
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Figure 2. Illustration of C’ dot synthesis system with Cy5 and FITC as examples of 
primary and secondary dyes. 
 
We demonstrate two different SNPS designs (Figure 3C). In design one, MB2 
is encapsulated within the silica network of an ultrasmall poly(ethylene glycol) coated 
(PEGylated) SNP; in design two, MB2 is grafted onto the SNP surface, inserted between 
the PEG corona chains. In both cases the PS molecules are covalently bound to the 
SNPSs via a thiol-Michael addition click reaction between maleimide functionalized 
MB2 and (3-mercaptopropyl)trimethoxysilane (MPTMS). We show that both particle 
types can be further functionalized with the αvβ3 integrin-targeting cyclic(arginine-
glycine-aspartic acid-D-tyrosine-cysteine) peptide (cRGDyC, Figure 3D). 
Photosensitizing action is successfully demonstrated using the singlet oxygen sensor 
1,3-diphenylisobenzofuran (DPBF, inset Figure 5A). We demonstrate effective per 
particle singlet oxygen quantum yields of 111% (design one) and 161% (design two), 
respectively. 
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CHAPTER 2 
INTRODUCTION  
 
2.1 Background 
Photodynamic therapy (PDT) emerged as a minimally invasive and minimally 
toxic therapeutic modality for the treatment of cancer and other diseases [1]. The 
principle of PDT can generally be described in four steps: A photosensitizer (PS) is 
localized around diseased tissue (step 1) and activated by a light source (step 2). The 
absorbed photon energy leads to the generation of highly reactive singlet oxygen, 1O2 
(step 3), causing oxidative stress and cellular damage, eventually initiating cell death 
mechanisms such as necrosis and/or apoptosis in the local environment of the PS (step 
4) [14]. These steps impose chemical, photophysical, and structural requirements onto 
PDT probes. 
Photophysical requirements: A PS has unique photophysical characteristics. 
Generation of 1O2 is catalyzed by photoexcitation of the PS. Figure 3A depicts a 
simplified Jablonski scheme illustrating the photophysical processes leading to 1O2 
generation. From an electronically excited singlet state the PS undergoes a forbidden 
electron spin-flip (intersystem crossing, ISC) into an energetically lower lying excited 
triplet state, 3PS*. From here, 3PS* relaxes into the singlet ground state, 1PS, via energy 
transfer (ET) with dissolved molecular triplet oxygen, 3O2, yielding cytotoxic reactive 
singlet oxygen, 1O2. High intersystem crossing rates (kISC) and long triplet state lifetimes 
(τT > 1 µs) of the PS promote 1O2 generation, which is reflected in high singlet oxygen 
quantum yields, ΦΔ [15]. An ideal PS should have a molar extinction coefficient of ε ≥ 
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50 000 M-1 cm-1 [15][16] in the therapeutic window of ~600–1200 nm [17] and a singlet 
oxygen quantum yield of ΦΔ ≥ 0.5 [16]. In addition, high photostability, as well as low 
phototoxicity in the dark are desired. 
Chemical requirements: Besides the general requirement of a PDT probe to be 
non-toxic itself, a key challenge is its localization at a specific site of interest. Singlet 
oxygen is highly reactive, and locally produced by the PS. Typical diffusion lengths of 
singlet oxygen in tissue before it reacts are on the order of tens of nanometers [18]. 
Therefore, to minimize damage of healthy tissue, selective targeting is crucial. Since 
most PS molecules are hydrophobic and prone to aggregation in physiological 
environments, low selectivity towards diseased tissue and adverse pharmacokinetics 
have hindered their clinical translation [19][20][16]. Nanoparticles (NPs) as PS delivery 
vehicles can promote solubility, overcome aggregation issues to improve 
pharmacokinetics, and protect PSs from enzymatic degradation [21][22]. Furthermore, 
NP surface functionalization with targeting moieties reduces systemic side effects, 
increases the therapeutic concentration of PSs at the target site, and gives room for 
multi-modality platforms simultaneously enabling diagnosis, imaging, and treatment 
[22]. However, while NP-based PS systems help overcome shortages associates with 
the PS molecules, they themselves impose additional requirements. 
Structural requirements: First, since PSs are bound to NPs and don’t have to be 
released, it is essential that oxygen species can easily diffuse to and away from the PS 
molecule. Second, after NPs have targeted the site of interest and PDT has been 
performed (or if the NPs have failed to target the site of disease in the first place) it is 
essential that they are rapidly cleared from the body to reduce potential side effects 
  7 
(principle of target-or-clear [23]). Both of these requirements favor small 
hydrodynamic diameters leading to rapid renal clearance via the kidneys with a cutoff 
for spherical NPs below 10 nm hydrodynamic diameter [24].  
 
2.2 Motivations 
Different NP-based systems, organic, inorganic, and organic-inorganic hybrid, 
have been described in the literature, including PEGylated liposomes, polymeric NPs,  
iron oxide NPs, or gold NPs [7][25][26][27]. While numerous NPs systems are able to 
load large amounts of PS molecules, few NP platforms combine the necessary ease of 
chemical functionalization with precise particle size control on the sub-10 nm length 
scale, to meet stringent requirements for successful clinical translation and synthesis 
scale-up [28][29][30]. While metal-organic framework NPs in principle offer these 
capabilities, targeted delivery and systematic in vitro and in vivo studies on NP activity 
and fate demonstrating favorable characteristics are still lacking [31].  
Ultrasmall organic-inorganic hybrid silica nanoparticles (SNPs) meet these 
requirements today. It has been demonstrated in first published human clinical trials that 
fluorescent sub-10 nm PEGylated and functionalized SNPs efficiently target and clear 
from the human body [32][33]. In addition, the chemical inertness, optical transparency 
of silica, and cost-effective water-based synthesis paired with exceptional size and 
structural control on the sub-nanometer length scale, insusceptibility to swelling due to 
pH changes, and high silica matrix porosity render such particles ideal candidates for 
PDT [8][17][34][35][36].   
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CHAPTER 3 
METHODS AND RESULTS 
 
3.1 Background 
As ultrasmall PEGylated silica nanoparticles (C’ dots) provide a potential 
platform as a satisfactory carrier to deliver photosensitizers into tumor site to apply 
PDT, we are interested in investigating the photo-properties of C’ dots encapsulating 
photosensitizer dyes. In order to use the well-established syntheses of C’ dot to 
incorporate the photosensitizer dye, a water-soluble and photostable photosensitizer is 
required. Here, for the photosensitizer, we choose MB2, a water-soluble Type II 
photosensitizer derived from methylene blue (MB) which lies advantage in its high 
singlet oxygen quantum yield and extinction coefficient in the near infrared (ΦΔ ≈0.5, ε 
= 105 M-1 cm-1 at 664 nm). Since MB has been approved for clinical translation by the 
U.S.  Food and Drug Administration (FDA) and has been used in photodynamic 
therapy[9][10], it leaves potential of clinical translation for MB2 encapsulated C’ dots 
as a novel PDT probe.  
In this chapter, we introduce ultrasmall sub-10nm organic-inorganic hybrid 
silica nanoparticles (SNPs) covalently binding the photosensitizer dye MB2 (Figure 3B 
and Figure A1). In the following we will refer to these particles as silica 
nanophotosensitizers (SNPSs). We demonstrate two different SNPS designs (Figure 
3C). In design one, MB2 is encapsulated within the silica network of an ultrasmall 
poly(ethylene glycol) coated (PEGylated) SNP; in design two, MB2 is grafted onto the 
SNP surface, inserted between the PEG corona chains. In both cases the PS molecules 
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are covalently bound to the SNPSs via a thiol-Michael addition click reaction between 
maleimide functionalized MB2 and (3-mercaptopropyl)trimethoxysilane (MPTMS). 
We show that both particle types can be further functionalized with the αvβ3 integrin-
targeting cyclic(arginine-glycine-aspartic acid-D-tyrosine-cysteine) peptide (cRGDyC, 
Figure 3D). Photosensitizing action is successfully demonstrated using the singlet 
oxygen sensor 1,3-diphenylisobenzofuran (DPBF, inset Figure 5A). We demonstrate 
effective per particle singlet oxygen quantum yields of 111% (design one) and 161% 
(design two), respectively. Despite earlier attempts to synthesize MB containing SNPs, 
to the best of our knowledge sub-10 nm functionalized SNPs covalently binding MB 
have not been reported to date [9][37][38]. 
 
3.2 Materials and Methods 
3.2.1 Materials 
Aluminum-tri-sec-butoxide (ASB), (3-aminopropyl)triethoxysilane (APTES), 
ammonium hydroxide (28 wt% in H2O),  ammonia solution (2.0 M in ethanol), dimethyl 
sulfoxide (DMSO), 1,3-diphenylisobenzofuran (DPBF, 97%), hydrochloric acid (HCl, 
0.5018 N in H2O), (3-iodopropyl)trimethoxysilane (IPTMS), methylene blue (MB), (3-
mercaptopropyl) trimethoxysilane (MPTMS), 2-propanol (anhydrous 99.5%), and 
tetramethyl orthosilicate (TMOS) were purchased from Sigma Aldrich. (3-
aminopropyl)trimethoxysilane (APTMS) and methoxy-terminated poly(ethylene 
glycol) (PEG-silane, molar mass of ~0.5 kg/mol) were purchased from Gelest. 
Heterobifunctional PEG (NHS-PEG-mal, molar mass of ∼960 g/mol) was purchased 
from Quanta BioDesign. ATTO MB2-maleimide was purchased from ATTO-Tec. 
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Tetramethylrhodamine-5-maleimide (TMR) was purchased from AnaSpec. Ethanol 
(absolute anhydrous 99.5%) was purchased from Pharmco-Aaper. c(RGDyC) was 
purchased from Peptide International. Deionized (DI) water (18.2 MΩ·cm) was 
generated using a Millipore Milli-Q system. All chemicals were used as received. 
3.2.2 Synthesis of Nanophotosensitizers (Design One) 
First, 3.67x10-7 moles MB2 with a maleimide group are reacted with MPTMS 
in DMSO at a molar ratio of 1:25 (fluorophore:MPTMS) to generate a MB2-silane 
conjugate. To synthesize sub-10 nm PEGylated SNPs with MB2 inside the silica core, 
2 mL of 0.02 M ammonia aqueous solution is first added into 8 mL of DI water yielding 
a pH of ~9. The solution is then stirred at room temperature for 5 min. As the silica 
precursor, 0.43 mmol of TMOS are added under vigorous stirring, followed by the 
addition of all MB2-silane. The molar ratio of MB2-silane to TMOS is about 1:1000. 
The solution is left stirring at room temperature overnight. Then, 0.21 mmol of PEG-
silane are added and the solution is kept stirring at room temperature overnight. Finally, 
to promote covalent bond formation between PEG-silane and particles, stirring is 
stopped and the particle dispersion is heated to 80 °C for 8 hours. To remove any 
unreacted precursors, aggregates, or dust from the particle dispersion, particles are 
transferred into a dialysis membrane tube (molecular weight cutoff, MWCO = 10,000), 
and dialyzed in 2 L of DI water with three water exchanges every 8 hours. After dialysis, 
the dispersion is subject to syringe filtration (0.2 µm, Fisherbrand) and finally up-
concentrated for gel permeation chromatography (GPC) using a membrane spin filter 
(GE Healthcare, molecular weight cutoff = 30,000) and a centrifuge at 2300 rpm.  
3.2.3 Synthesis of Nanophotosensitizers (Design Two) 
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Particles binding MB2 to the particle surface are synthesized according to the 
synthesis of design one (excluding the addition of MB2-silane, or replacing MB2 with 
TMR-maleimide, see main text). MB2 is added to the final silica particles by using the 
method of post-PEGylation surface modifications by insertion (PPSMI) [8]. To that end, 
MPTMS is added to the PEGylated particle dispersion under vigorous stirring at a 
concentration of 2.3 mM. The particle/MPTMS mixture is stirred at room temperature 
overnight, followed by the addition of 3.67x10-7 moles MB2-maleimide at a 
concentration of 37 µM. The solution is vigorously stirred at room temperature for 24 
hours for the dye to react with the thiol group on the silica core surface of the particles. 
Afterwards, the particle dispersion is subjected to the same cleaning process as 
described before (dialysis, syringe filtration, GPC). Particles containing TMR on the 
surface were synthesized in the same way by replacing MB2-maleimide with TMR-
maleimide. 
3.2.4 Targeting Peptide c(RGDyC) Functionalization 
Particles were peptide-functionalized with c(RGDyC)-PEG-silane 
(Supplementary Figure A3). c(RGDyC)-PEG-silane was prepared by exploiting the 
mercapto group of cysteine of c(RGDyC) (Figure 3D) to click to the maleimide group 
of a heterobifunctional mal-PEG-NHS first, and then clicking the NHS to the amine 
group of (3-aminopropyl)trimethoxysilane (APTES). The concentration of NHS ester-
PEG-maleimide in DMSO was 0.23 M. The mixed solution was left at room temperature 
in the glovebox for 3 hours to form silane-PEG-maleimide. After that, c(RGDyC) was 
added and the solution left at room temperature in the glovebox overnight to produce 
c(RGDyC)-PEG-silane. The molar ratio c(RGDyC):NHS-PEG-mal:APTES was 
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1.0:1.0:0.9. In order to functionalize particles with c(RGDyC) peptide ligands, 
previously prepared c(RGDyC)-PEG-silane was added to the particle dispersion 
immediately before the addition of PEG-silane. The remainder of the synthesis and 
purification protocol is as described before. 
3.2.5 Gel Permeation Chromatography (GPC) 
To remove unreacted precursors from the native particle dispersion, samples 
were purified using gel permeation chromatography (GPC). A BioLogic LP system with 
275 nm UV detector and cross-linked copolymer of allyl dextran and N,N'-methylene 
bisacrylamide (Sephacryl S-300 HR, GE Healthcare) as solid phase was used. Before 
GPC purification each sample was up-concentrated with centrifuge spin-filters 
(Vivaspin with MWCO 30k, GE Healthcare) to an approximate sample volume of 600 
µL, run through the column with a 0.9 wt% NaCl solution, and fraction-collected by a 
BioFrac fraction collector. Sample fractions were transferred to DI water by washing 
samples five times with centrifuge spin-filters. The resulting particles could be 
subjected to long-term storage in nitrogen bubbled DI water in the dark at 4 °C. 
3.2.6 Steady State Absorption Spectroscopy 
Absorbance spectra were measured on a Varian Cary 5000 spectrophotometer. 
Spectra were measured in DI water using a quartz cuvette (HellmaAnalytics) with a 10 
mm light path, and baseline corrected using a second cuvette with pure DI water as a 
reference cell. All spectra were measured in 1 nm increments and peak intensities were 
kept between 0.01 and 0.06. 
3.2.7 Fluorescence Correlation Spectroscopy (FCS) 
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A homebuilt confocal FCS setup was used to determine particle hydrodynamic 
diameter, solution concentration, and number of dye molecules per particle. Particles 
containing TMR dye were excited with a 543 nm He:Ne laser, that was focused by a 
water immersion microscope objective (Zeiss Plan-Neofluar 63x NA 1.2). The 
fluorescence signal passed through a 50 µm pinhole and a long pass filter (ET560lp, 
Chroma) before being detected by an avalanche photo diode (APD) detector (SPCM-
AQR-14, PerkinElmer) and auto-correlated with a digital correlator (Flex03LQ, 
Correlator.com). Data was fitted using a non-linear least-squares Levenberg-Marquardt 
algorithm and a triplet corrected correlation function, G(t), shown in equation (1):  
𝐺(𝜏) = 1 + 1𝑁* + 11 + 𝜏 𝜏,⁄ . + 11 + 𝜏 (𝜏,𝜅0)⁄ .1 0⁄ 1(1 − 𝑇) (1 − 𝑇+ 𝑇 exp(𝜏 𝜏7⁄ )) (1) 
Where 𝜏 is the lag time, 𝑁* the time- and spaced-averaged number of TMR labeled 
particles in the FCS observation volume, that is defined by a structure factor κ =ω: ω;<⁄  with radial (ω;<) and axial (ω:) radii. 𝜏, is the time that a particle takes to 
diffuse through the observation volume. 𝑇 is the fraction of TMR molecules being in 
the triplet state, with a triplet relaxation time, 𝜏7. FCS correlation curves were 
normalized using equation (2): 𝐺(𝜏) = (𝐺(𝜏) − 1)	𝑁* (2) 
All samples were measured in 35 mm glass bottom dishes (P35G-1.5-10-C, Mattek 
Corporation) at nanomolar concentration in DI water at 20 °C, 5 kW cm-2 laser power, 
and in triplets with five 30 s long collection intervals. The observation volume was 
calibrated before each FCS measurement. Particle diameters, 𝑑, were calculated using 
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the Stokes-Einstein equation (3) with the diffusion constant,	𝐷, obtained from equation 
(4): 
𝑑 = 2 𝑘B𝑇6𝜋𝜂𝐷 (3) 
𝐷 = ω;<04𝜏,  (4) 
The number of TMR or MB2 molecules per particle, 𝑛*, was determined by comparing 
the dye concentration from steady state absorption spectroscopy, CAbs, and the particle 
concentration measured in FCS, <C>FCS, using equation (5): 
𝑛* = 𝐶IJK〈𝐶〉NOP (5) 
where it was assumed that the molar extinction coefficients do not change upon dye 
encapsulation. 
3.2.8 Determination of Singlet Oxygen Quantum Yields, Φ∆ 
Singlet oxygen quantum yield, Φ∆, measurements were carried out in ethanol 
with 1,3-diphenylisobenzofuran (DPBF) as a detector molecule for trapping singlet 
oxygen. The generation of singlet oxygen could be observed by a reduction of the DPBF 
absorption band at 410 nm (Figure 5A). Measurements were carried out at sample 
optical densities of 0.15 – 0.50 in a 100 µL quartz cuvette (Starna). Samples were evenly 
exposed to a 635 nm, expanded, and collimated laser beam of a solid-state laser (Power 
Technology Inc.) at 3 mW/cm2 with a spot size of about 1 cm in the same cell. To 
acquire a 0.5 - 0.6 absorption, DPBF was added at a concentration of approximately 
18.75 µM. All absorption spectra were measured in 1 nm steps and baseline-corrected 
against a second cuvette with ethanol as a reference cell. The sample absorption was 
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recorded at defined time intervals and corrected for the sample absorption spectrum in 
the absence of DPBF. Φ∆ was calculated by comparing all samples to the standard 
methylene blue (MB) dye with known singlet oxygen quantum yield of Φ∆ = 0.52 (in 
ethanol) [39] by plotting the natural logarithm of the reduction of the 410 nm DBPF 
band against the exposure time and using equation (6), where 𝑚 represents the slope of 
a linear fit through the data points (Figure 5B): 
Φ∆(𝑠𝑎𝑚𝑝𝑙𝑒) = Φ∆(𝑀𝐵)𝑚(𝑠𝑎𝑚𝑝𝑙𝑒)𝑚(𝑀𝐵)  (6) 
To determine the effective singlet oxygen quantum yield, Φ∆eff, the particle 
concentration as determined by FCS and the MB concentration were matched.  
 
3.3 Results and Discussion 
Silica nanophotosensizers (SNPSs) covalently encapsulating the methylene blue 
derivate MB2 inside the particle (design one, Figure 3C) were synthesized by combining 
tetramethylorthosilcate (TMOS) and MB2-silane (Figure 3B) in basic aqueous solution. 
After particle formation, further particle growth was quenched by the addition of PEG-
silane (Figure 3B) to the reaction mixture. Particles containing MB2 on the particle 
surface (design two, Figure 3C) were synthesized in the same way, however, MB2 was 
attached using a grafting method referred to as post-PEGylation surface modification 
by insertion (PPSMI) [8]. This method employs amine-reactive or sulfhydryl-reactive 
click chemistry, by adding amine-silanes or thiol-silanes, respectively, below the 
nucleation threshold into an aqueous dispersion of PEGylated SNPs. The small molar 
mass silane precursors diffuse through the PEG corona chains and react with the silica   
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Figure 3. (A) Simplified Jablonski Scheme illustrating the creation of reactive singlet 
oxygen, 1O2. 1PS denotes the singlet ground state, 1PS* the electronically excited singlet 
state, and 3PS* the electronically excited triplet state of a photosensitizer. 3O2 denotes 
the triplet ground state of molecularly dissolved oxygen. (B) Precursor molecules for 
the synthesis of sub-10 nm silica nanoparticles, showing the MB2-silane, the rhodamine 
dye TMR-silane, tetramethyl orthosilicate (TMOS), and polyethylene glycol-silane 
(PEG-silane). (C) Schematic representation of two different designs of functionalized 
photosensitizing sub-10 nm silica nanoparticles (center). Design 1: Covalent 
encapsulation of one or more MB2 molecules in the silica matrix (PEG-MB2-C’ dots). 
Design 2: Particle surface functionalization with one or more MB2 molecules (MB2-
PEG-C’dot). (D) Targeting moiety cyclo(Arg-Gly-Asp-D-Tyr-Cys) (cRGDyC).
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particle surface. The pending amine or thiol groups can further be reacted with N-
hydroxysuccinimide or maleimide functional groups, respectively [8]. For design two, 
we used (3-mercaptopropyl)trimethoxysilane (MPTMS) to functionalize the particle 
surface with thiol groups to click MB2-maleimide to the particle (for details see Section 
3.2.3). Finally, all particles were cleaned from unreacted precursors via gel permeation 
chromatography (GPC) prior to further characterization.  
Due to the weakly-emissive nature of MB2 (Supplementary Figure A2), 
fluorescence-based size determination of MB2 functionalized particles by fluorescence 
correlation spectroscopy (FCS) was not possible. To make particle samples accessible 
for the determination of hydrodynamic diameters and particle concentrations by FCS, 
particles were further functionalized with the fluorescent dye tetramethylrhodamine-
silane (TMR-silane) (Figure 3B). For design one we grafted TMR onto the particle 
surface using PPSMI and for design two we synthesized SNPs encapsulating TMR dye 
before MB2 was grafted on the particle surface. A combination of FCS and steady state 
absorption spectroscopy was used to determine the number of MB2 and TMR molecules 
per particle. Particle diameter and concentration were determined by measuring the 
fluorescence fluctuations of particles diffusing through a well-defined observation 
volume of a laser beam and subsequently auto-correlating the fluorescence time signal. 
The resulting FCS correlation curves were fitted with a correlation function (see 
equation (1), Section 3.2.7) from which the time averaged number of particles and the 
diffusion constant were extracted. To determine the number of dyes per particle, the dye 
concentration as determined by steady-state absorption spectroscopy was compared to 
the concentration of the particles as determined by FCS (equation (5), Section 3.2.7), 
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yielding the average number of dyes per particle. For accurately determining the number 
of MB2 dyes per particle, it is necessary that every MB2 containing particle carries at 
least one TMR dye, a requirement that is not necessarily met. We accounted for that to 
the best possible degree by working with high concentrations of TMR. Dye molecules 
that were not covalently bound during synthesis were washed away by dialysis and 
separated from the particles by GPC. Supplementary Figure A4A and A4B show the 
GPC chromatograms before and after TMR and MB2 surface functionalization of 
particles, respectively. Both chromatogram-pairs show a single peak and were 
congruent to each other, indicating that TMR dye molecules (design one), or MB2 dye 
molecules (design two) were grafted onto the respective SNPs.  
Figure 4A and 4B show the FCS correlation curves of the fluorescent particles. 
The curves were fitted using a triplet corrected translational diffusion correlation 
function (equation (1), Section 3.2.7). Particle hydrodynamic diameters of 5.9 nm for 
MB2 encapsulating C’ dots with TMR surface functionalization (TMR-PEG-MB2-C’ 
dots), 5.2 nm for TMR encapsulating C’ dots (PEG-TMR-C’ dots), and 5.2 nm for TMR 
encapsulating C’ dots with MB2 surface functionalization (MB2-PEG-TMR-C’ dots) 
were obtained (a comprehensive nomenclature to describe C’ dots is described in the 
supporting information of reference [8]). Figure 4C and 4D show the UV-vis absorption 
spectra of PEG-MB2-C’ dots, TMR-PEG-MB2-C’ dots, PEG-TMR-C’ dots, and MB2-
PEG-TMR-C’ dots in water, respectively. For comparison, the absorption spectra of 
TMR-maleimide and MB2-maleimide are superimposed onto the particle spectra. For 
TMR-PEG-MB2-C’ dots and MB2-PEG-TMR-C’ dots, a TMR absorption   
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Figure 4. (A) and (C) FCS autocorrelation curve of MB2-PEG-TMR-C’dot (design 
one) and absorption spectra before and after TMR surface functionalization as compared 
to free TMR dye and MB2 photosensitizer. (B) and (D) FCS autocorrelation curves of 
PEG-TMR-C’ dots and TMR-PEG-MB2-C’ dots (design two) and absorption spectra 
before and after MB2 surface functionalization as compared to free TMR dye and MB2 
photosensitizer. 
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peak can be observed indicating successful functionalization of particles with TMR and 
MB2, respectively.  
Comparing the absorption profiles of MB2 for the two different designs, a 
relative hypsochromic shift (blue-shift) from 668 nm to 644 nm of the main peak for 
design one relative to free MB2 is observed that is absent in design two. This 
hypsochromic shift likely originates from dimethylation of the auxochrome groups of 
MB2, from -N(CH3)2 to -NH(CH3) and/or -NH2, which is promoted in basic media 
[40][41]. In addition, both designs display a heightened left shoulder in the absorption 
peak as compared to free MB2 dye that is more pronounced in design one than it is in 
design two. The heightened shoulders around 620 nm and 605 nm for design two and 
one, respectively, are a result of dimerization of MB2 at high concentrations (1×10−6 to 
4×10−4 M) in aqueous media (MB2 concentrations during synthesis is 3.67x10-5 M) 
[42]. Methylene blue monomers and dimers are known to have distinct absorption peaks 
located at 664 nm and 590 nm, respectively, with an equilibrium constant of 3.8x103 M-
1 in water [43]. However, the formation of dimers is not only dependent on concentration 
but is additionally promoted by the presence of oppositely charged surfaces [44]. For 
design one, the cationic MB2 photosensitizer was added to the synthesis during the silica 
particles formation and hence was exposed to negatively charged silica nucleation seeds 
(at pH 9). For design two, MB2 was grafted onto the PEGylated silica particle surface 
at neutral conditions (pH 7), consequently showing no peak shift and relatively fewer 
MB2 dimers, despite the same MB2 concentration during the synthesis as for design 
one.  
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 To determine the number of MB2 molecules per particle we compared the 
particle concentrations estimated by FCS and the MB2 concentrations from steady-state 
absorption measurements. For practical reasons, we assumed that the extinction 
coefficient remained unaffected in the particle synthesis. This is not necessarily true due 
to the metachromatic nature of methylene blue and demethylation. Based on this 
assumption we estimated the average number of dyes per particle (equation (5), Section 
3.2.7) to be 2.4/3.3 for MB2/TMR for design one and 3.4/2.3 for MB2/TMR for design 
two.  
Next, we measured the singlet oxygen quantum yield, Φ∆, for both particle 
designs using the singlet oxygen sensor 1,3-diphenylisobenzofuran (DPBF). For these 
measurements, we matched the particle concentrations as determined by FCS to yield 
an effective singlet oxygen quantum yield per SNPS (ΦΔeff (SNPS)). Figure 5A 
demonstrates the principle of oxygen sensing using DPBF and the particle TMR-PEG-
MB2-C’ dots (design one) in ethanol. The mixture is evenly exposed to an expanded 
and collimated 635 nm laser beam for defined time intervals. The singlet oxygen that is 
generated by the SNPSs reacts with DPBF molecules, yielding 1,2-dibenzoylbenzene 
[45]. The formation of 1,2-dibenzoylbenzene was monitored via a reduction of the 
absorption band at 410 nm. By comparing samples to a methylene blue standard 
(ΦΔ(MB) = 0.52), ΦΔeff(SNPS) was determined (see equation (6), Section 3.2.7), 
resulting in values of 111% for design one (TMR-PEG-MB2-C’ dots) and 161% for 
design two (MB2-PEG-TMR-C’ dots). This translates to an estimated per dye singlet 
oxygen quantum yield of 46% and 47%, respectively, based on the estimated number 
of MB2 dyes per particle. The relatively lower values for ΦΔ of the dyes associated with  
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Figure 5. (A) Schematic representation of a photosensitizing measurement using 1,3-
diphenylisobenzofuran (DPBF) as a singlet oxygen, 1O2, sensor. Absorption of a 
solution containing TMR-PEG-MB2-C’ dots and DPBF irradiated at 635 nm for 60 s in 
intervals of 5 s (see legend). (B) Comparative 1O2 generation of methylene blue, TMR-
PEG-MB2-C’ dots, and MB2-PEG-TMR-C’ dots.  
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the particles versus free methylene blue dye can be rationalized by the steric shielding 
effects of encapsulation or grafting within the PEGylation corona. The silica network 
and/or the PEG molecules shield diffusing oxygen, first, from MB2, and then, from 
DPBF resulting in a reduced singlet oxygen quantum yield. Although for both designs 
the per dye ΦΔ values are similar, surface grafted MB2 molecules are likely less shielded 
than dyes fully encapsulated in the silica network. In addition, it is known that 
methylene blue dimers and monomers engage in different photochemical processes. 
While monomers undergo energy transfer reaction with triplet oxygen, dimers engage 
in electron transfer reactions with other methylene blue molecules [43]. These different 
energy dissipation pathways of dimers correlate negatively with the singlet oxygen 
quantum yield contributing to the reduced singlet oxygen quantum yield per dye 
molecule of design one and design two [46]. However, the multiplicity effect stemming 
from multiple MB2 molecules colocalized on one particle compensates for a reduced 
per dye singlet oxygen quantum yield by steric shielding and/or dimerization.  
To exclude the possibility of 1O2 formation in the absence of irradiation with 
light (dark toxicity) for the different particle designs, we repeated singlet oxygen 
quantum yield measurements, but did not expose the samples to the laser beam. 
Supplementary Figure A5 shows results of the same experiment as shown in Figure 5A 
for design one (PEG-MB2-C’ dots). This time, the DPBF peak at 410 nm remains 
unchanged, however, indicating no formation of 1,2-dibenzoylbenzene and hence no 
generation of singlet oxygen. This is the case for both designs.  
Specific targeting of photosensitizers to diseased tissue increases the efficacy of 
PDT and minimizes collateral damage to healthy tissue. We therefore functionalized 
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SNPSs with the targeting moiety cyclo(arginine-glycine-aspartic acid-D-tyrosine-
cysteine) (c(RGDyC)) (Figure 3C), which targets αvβ3 integrins overexpressed, e.g. on 
various cancer cells including melanoma [33]. It has been shown that the endocytosis-
mediated cellular uptake of c(RGDyC) functionalized particles correlates with the αvβ3-
expression levels of cells [47][48], and increases the intracellular particle concentration, 
rendering c(RGDyC) a specific targeting moiety with high affinity for the treatment of 
the melanoma cancer [23][49]. 
Particles were functionalized by adding c(RGDyC)-PEG-silane (Supplemenatry 
Figure A3A) during the PEGylation step (for details see Section 3.2.4) [34]. To allow 
more steric freedom for ligand binding to integrins, the c(RGDyC)-PEG-silane was 
chosen to be three ethylene oxide (EO) units longer than the PEG-silane (twelve versus 
six-nine units). Due to the weakly-fluorescent nature of MB2, an FCS analysis could 
not be conducted. Instead we compared the GPC chromatograms before and after 
peptide functionalization for particle design one (PEG-MB2-C’ dots and c(RGDyC)-
PEG-MB2-C’ dots), and two (MB2-PEG-C’ dots and MB2-c(RGDyC)-PEG-C’ dots) 
(Supplementary Figures A6A and A6B). In both cases, we observed single peaks that 
were congruent to each other. All particles were then characterized using steady-state 
absorption spectroscopy. Figure 6A and 6D show the absorption spectra of design one 
and design two, respectively, with and without c(RGDyC)-functionalization in water. 
In both cases, increased absorption between 200 and 300 nm was noticeable. Due to 
strong absorption features in that region it is difficult to clearly identify the peptide 
absorption by qualitative comparison. For that reason, we deconvoluted the two spectra 
and display the difference spectra in Figures 6B and 6E. In both cases a band at ~260 to   
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Figure 6. (A) Intensity matched absorption spectra of PEG-MB2-C’ dots and 
c(RGDyC)-PEG-MB2-C’ dots. (B) Difference spectrum of the spectra in (A). (C) 
Photosensitizing measurement of intensity matched PEG-MB2-C’ dots and c(RGDyC)-
PEG-MB2-C’ dots. (D) Intensity matched absorption spectra of MB2-PEG-C’ dots and 
MB2-c(RGDyC)-PEG-C’ dots. (E) Difference spectrum of the spectra in (D). (F) 
Photosensitizing measurement of intensity matched MB2-PEG-C’ dots and MB2-
c(RGDyC)-PEG-C’ dots.  
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270 nm can clearly be identified, which coincides with the absorption band of the 
c(RGDyC) spectrum (Supplementary Figures A6C). Using the relative absorption peaks 
of tyrosine in c(RGDyC) and of MB2, we estimated 17 and 14 c(RGDyC) units per 
MB2 molecule for design one and design two, respectively, which is close to the desired 
number based on earlier studies [49].  
 Finally, we tested the effect of c(RGDyC)-functionalization on the relative 
singlet oxygen quantum yield performance. We compared particles with and without 
c(RGDyC) for absorption matched samples of the same design. For both designs we 
measured a reduction of singlet oxygen quantum yield by a relative 25% for design one 
and by a relative 12% for design two (Figure 6C and 6F). This finding is surprising. 
Given the spatial proximity of surface MB2 and c(RGDyC), one would expect a stronger 
effect of c(RGDyC) in design two. Results suggest, however, that c(RGDyC) increases 
the steric shielding more significantly for the encapsulated MB2 than for the surface 
grafted MB2. 
 
3.4 Contributions 
Chapter 2 and 3 of this thesis are based on the manuscript named ‘Designing 
PEGylated and Functionalized Sub-10 nm Silica Methylene Blue Nanophotosensitizers’ 
with co-first authorship between Ferdinand F. E. Kohle and me. F. F. E. Kohle and I 
synthesized nanoparticles and conducted steady-state absorption and emission 
spectroscopy. F. F. E. Kohle helped me with analysis of steady-state absorption and 
emission spectroscopy and conducted FCS measurements. F. F. E. Kohle and I carried 
out singlet oxygen quantum yield measurements.  
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CHAPTER 4 
CONCLUSIONS AND FUTURE WORK 
 
4.1 Conclusions 
In this thesis, we have presented the synthesis of two different designs for 
ultrasmall organic-inorganic hybrid silica nanophotosenistizers, that covalently bind the 
methylene blue derivate MB2. We found that the properties of MB2 strongly depend on 
the particle design. Both particle designs yielded sub-10 nm size particles that could be 
functionalized with c(RGDyC) as a targeting moiety. Despite reduced singlet oxygen 
quantum yields of MB2 upon particle association, the effective particle singlet oxygen 
quantum yields far exceed the quantum yield of a single MB2 dye. The advantages of 
ultrasmall organic-inorganic hybrid functionalized silica nanoparticles as a delivery and 
protective system for photosensitizers make such probes interesting candidates for 
applications in PDT.  
 
4.2 Future Work 
Although this thesis focuses on the photosensitizer MB2, described design 
principles and synthesis methods are in principle applicable to other photosensitizers. 
This might be of special interest for hydrophobic NIR and IR photosensitizers with large 
singlet oxygen quantum yields, i.e. porphyrins, chlorins, phthalocyanines, 
naphthalocyanines, bacteriochlorins, and BODIPY dyes. PEGylated silica can provide 
a water-soluble carrier for these cargos, to allow specific targeting and achieve high 
local concentrations at targeted sites, while avoiding aggregation in aqueous media. 
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However, more work is necessary to fine tune such synthesis protocols to fully harvest 
the potential of ultrasmall organic-inorganic hybrid silica nanophotosenistizers. 
Moreover, subsequent in vitro and in vivo experiments are required for practical PDT 
applications to test the singlet oxygen quantum yield of SNPSs in cells, which will offer 
guidelines to potential clinical translations in the future.  
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APPENDIX 
 
 
 
Figure A1. Methylene blue (MB) and MB2 absorption spectra. A minor bathochromic 
shift (red-shift) from 665 to 667 nm is noticeable. The inset shows the chemical structure 
of MB with auxochrome groups circled in blue.  
 
 
 
Figure A2. Fluorescence emission spectra of Cy5 dye, PEG-Cy5-C’ dots, MB2, PEG-
MB2-C’ dots, and MB2-PEG-C’ dots. The concentration of Cy5 and MB2 was matched. 
The emission spectra were normalized for the emission of MB2. The inset shows the 
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enlarged emission of MB2, PEG-MB2-C’ dots, and MB2-PEG-C’ dots, showing a more 
than one order of magnitude brightness difference between the Cy5 and PEG-Cy5-C’ 
dots and MB2, PEG-MB2-C’ dots, and MB2-PEG-C’ dots. Cy5 particles show the 
typical emission enhancement that is observed upon dye encapsulation in a silica matrix 
as compared to the free dye in solution [50] [51]. The emission of PEG-MB2-C’ dots as 
compared to MB2-PEG-C’ dots is slightly larger, however both particles demonstrate a 
reduction of emission as compared to free MB2. This can likely be associated with the 
increased shoulder of MB2 in the particles. 
 
 
 
Figure A3. (A) Chemical structure of the targeting moiety precursor (cRGDyC)-
PEG(12)-silane. (B) Chemical structure of (3-mercaptopropyl)trimethoxysilane 
(MPTMS). 
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Figure A4. (A) GPC elugrams of PEG-MB2-C’ dots (i) and TMR-PEG-MB2-C’ dots 
(ii). Inset shows photographs of the respective samples. (B) GPC elugrams of PEG-
TMR-C’ dots (i) and MB2-PEG-TMR-C’ dots (ii). Inset shows photographs of the 
respective samples. Each sample pair was measured on the same day. Different sample 
pairs were measured on different days leading to differences in absolute peak elution 
times. 
 
 
 
Figure A5. (A) Schematic representation of a photosensitizing measurement using 1,3-
diphenylisobenzofuran (DPBF) as a singlet oxygen, 1O2, sensor. Absorption of a 
solution containing PEG-MB2-C’ dots and DPBF, measured at different time points, in 
the absence of 635 nm irradiation (dark toxicity). (B) Comparison of singlet oxygen, 
1O2, generation from PEG-MB2-C’ dots and MB2-PEG-C’ dots in the dark. 
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Figure A6. (A) GPC elugrams of PEG-MB2-C’ dots (i) and c(RGDyC)-PEG-MB2-C’ 
dots (ii). Inset shows photographs of the respective samples. (B) GPC elugrams of MB2-
PEG-C’ dots (i) and MB2-c(RGDyC)-PEG-C’ dots (ii). Inset shows photographs of the 
respective samples. Each sample pair was measured on the same day. Different sample 
pairs were measured on different days leading to differences in absolute peak elution 
times. (C) Absorption spectrum of c(RGDyC) in water, showing an isolated tyrosin peak 
(ε ≈ 1400 M-1 cm-1) [34].  
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